^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Waldenstrom Macroglobulinemia
    Drug:Rituxan (rituximab) (CD20 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    The NCCN panel has included carfilzomib/rituximab/dexamethasone as a treatment option under other recommended regimens for Primary Therapy.
    Secondary therapy:
    carfilzomib
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Waldenstroms Macroglobulinaemia /Lymphoplasmacytic Lymphoma:...Preferred regimens...Bendamustine/rituximab....Other recommended regimens...Rituximab/cyclophosphamide/dexamethasone....Rituximab/cyclophosphamide/prednisone
    Secondary therapy:
    bendamustine; ; cyclophosphamide